SCM
IOVA icon

Silverarc Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Silverarc Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$464K – 97
2020
Q4 		$464K Buy
+10,000
New +$397K 0.27% 74

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Silverarc Capital Management's IOVA Position: Q1 2021 in Review

Silverarc Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 10,000 shares — an estimated $464K sold.

Silverarc Capital Management first reported a position in IOVA in Q4 2020 and held it in 1 quarter. The position peaked at $464K in Q4 2020. 251 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Silverarc Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 10,000 Iovance Biotherapeutics shares in Q1 2021, an estimated $464K.
  • Silverarc Capital Management first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Silverarc Capital Management's Iovance Biotherapeutics position peaked at $464K in Q4 2020.
  • 251 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.